Hypera S.A. Logo

Hypera S.A.

HYPMY

(4.0)
Stock Price

5,33 USD

13.71% ROA

14.73% ROE

12.85x PER

Market Cap.

22.722.595.873,23 USD

86.66% DER

3.35% Yield

20.82% NPM

Hypera S.A. Stock Analysis

Hypera S.A. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Hypera S.A. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (16.12%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 Revenue Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

4 Net Profit Growth

Over the last five years, this company's net profit has shown continuous growth, reflecting a robust financial performance and making it an attractive choice for potential investors.

5 Assets Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

6 Dividend

Investors can take comfort in the company's unwavering commitment to dividends, as it has consistently distributed payouts over the past five years, ensuring a reliable income stream.

7 PBV

The stock's PBV ratio (1.9x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

8 DER

The stock has a reasonable amount of debt compared to its ownership (87%), suggesting a balanced financial position and a moderate level of risk.

9 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

10 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (182) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

11 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

Hypera S.A. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Hypera S.A. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Hypera S.A. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Hypera S.A. Revenue
Year Revenue Growth
2005 346.700.000
2006 380.267.000 8.83%
2007 1.061.500.000 64.18%
2008 1.332.994.000 20.37%
2009 2.025.272.000 34.18%
2010 3.159.728.000 35.9%
2011 3.324.630.000 4.96%
2012 3.873.683.000 14.17%
2013 4.258.740.000 9.04%
2014 4.680.348.000 9.01%
2015 2.956.649.000 -58.3%
2016 3.288.747.000 10.1%
2017 3.638.458.000 9.61%
2018 3.724.309.000 2.31%
2019 3.294.749.000 -13.04%
2020 4.088.871.000 19.42%
2021 5.937.373.000 31.13%
2022 7.546.355.000 21.32%
2023 8.553.844.000 11.78%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Hypera S.A. Research and Development Expenses
Year Research and Development Expenses Growth
2005 0
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 73.916.000 100%
2019 128.717.000 42.57%
2020 151.651.000 15.12%
2021 126.693.000 -19.7%
2022 159.391.000 20.51%
2023 180.344.000 11.62%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Hypera S.A. General and Administrative Expenses
Year General and Administrative Expenses Growth
2005 19.000.000
2006 38.122.000 50.16%
2007 62.400.000 38.91%
2008 72.521.000 13.96%
2009 128.071.000 43.37%
2010 196.012.000 34.66%
2011 259.856.000 24.57%
2012 81.117.000 -220.35%
2013 207.465.000 60.9%
2014 225.853.000 8.14%
2015 149.960.000 -50.61%
2016 145.691.000 -2.93%
2017 172.424.000 15.5%
2018 49.805.000 -246.2%
2019 42.790.000 -16.39%
2020 48.190.000 11.21%
2021 67.423.000 28.53%
2022 92.806.000 27.35%
2023 78.236.000 -18.62%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Hypera S.A. EBITDA
Year EBITDA Growth
2005 48.500.000
2006 39.925.000 -21.48%
2007 228.400.000 82.52%
2008 313.183.000 27.07%
2009 553.217.000 43.39%
2010 808.512.000 31.58%
2011 802.557.000 -0.74%
2012 1.112.131.000 27.84%
2013 1.107.267.000 -0.44%
2014 1.217.159.000 9.03%
2015 1.134.590.000 -7.28%
2016 1.214.617.000 6.59%
2017 1.369.681.000 11.32%
2018 1.372.444.000 0.2%
2019 1.269.329.000 -8.12%
2020 1.519.862.000 16.48%
2021 2.169.978.000 29.96%
2022 2.811.735.000 22.82%
2023 3.353.596.000 16.16%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Hypera S.A. Gross Profit
Year Gross Profit Growth
2005 214.900.000
2006 192.457.000 -11.66%
2007 614.600.000 68.69%
2008 798.056.000 22.99%
2009 1.182.334.000 32.5%
2010 1.806.425.000 34.55%
2011 2.004.064.000 9.86%
2012 2.409.113.000 16.81%
2013 2.748.852.000 12.36%
2014 2.981.995.000 7.82%
2015 2.210.138.000 -34.92%
2016 2.441.960.000 9.49%
2017 2.711.712.000 9.95%
2018 2.665.277.000 -1.74%
2019 2.085.692.000 -27.79%
2020 2.629.275.000 20.67%
2021 3.802.886.000 30.86%
2022 4.761.524.000 20.13%
2023 5.415.244.000 12.07%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Hypera S.A. Net Profit
Year Net Profit Growth
2005 31.000.000
2006 -2.932.000 1157.3%
2007 42.100.000 106.96%
2008 -207.876.000 120.25%
2009 313.373.000 166.34%
2010 261.901.000 -19.65%
2011 -54.651.000 579.22%
2012 203.913.000 126.8%
2013 256.722.000 20.57%
2014 402.695.000 36.25%
2015 559.872.000 28.07%
2016 1.174.574.000 52.33%
2017 964.942.000 -21.72%
2018 1.129.601.000 14.58%
2019 1.164.040.000 2.96%
2020 1.295.116.000 10.12%
2021 1.330.208.000 2.64%
2022 1.696.697.000 21.6%
2023 1.997.712.000 15.07%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Hypera S.A. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2005 0
2006 0 0%
2007 0 0%
2008 -1 0%
2009 1 0%
2010 1 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 1 0%
2015 1 0%
2016 2 100%
2017 2 0%
2018 2 0%
2019 2 0%
2020 2 50%
2021 2 0%
2022 3 0%
2023 3 33.33%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Hypera S.A. Free Cashflow
Year Free Cashflow Growth
2008 -3.762.000
2009 148.714.000 102.53%
2010 -53.834.000 376.25%
2011 287.614.000 118.72%
2012 477.868.000 39.81%
2013 424.194.000 -12.65%
2014 460.125.000 7.81%
2015 66.349.000 -593.49%
2016 667.654.000 90.06%
2017 720.748.000 7.37%
2018 845.635.000 14.77%
2019 462.256.000 -82.94%
2020 -744.161.000 162.12%
2021 560.249.000 232.83%
2022 529.337.000 -5.84%
2023 542.313.000 2.39%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Hypera S.A. Operating Cashflow
Year Operating Cashflow Growth
2008 85.262.000
2009 193.504.000 55.94%
2010 67.236.000 -187.8%
2011 580.234.000 88.41%
2012 713.805.000 18.71%
2013 665.785.000 -7.21%
2014 664.001.000 -0.27%
2015 323.692.000 -105.13%
2016 881.756.000 63.29%
2017 932.612.000 5.45%
2018 1.066.494.000 12.55%
2019 823.882.000 -29.45%
2020 1.183.054.000 30.36%
2021 1.399.131.000 15.44%
2022 2.038.793.000 31.37%
2023 724.371.000 -181.46%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Hypera S.A. Capital Expenditure
Year Capital Expenditure Growth
2008 89.024.000
2009 44.790.000 -98.76%
2010 121.070.000 63%
2011 292.620.000 58.63%
2012 235.937.000 -24.02%
2013 241.591.000 2.34%
2014 203.876.000 -18.5%
2015 257.343.000 20.78%
2016 214.102.000 -20.2%
2017 211.864.000 -1.06%
2018 220.859.000 4.07%
2019 361.626.000 38.93%
2020 1.927.215.000 81.24%
2021 838.882.000 -129.74%
2022 1.509.456.000 44.42%
2023 182.058.000 -729.11%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Hypera S.A. Equity
Year Equity Growth
2005 40.300.000
2006 37.400.000 -7.75%
2007 691.329.000 94.59%
2008 1.916.528.000 63.93%
2009 3.437.310.000 44.24%
2010 5.059.091.000 32.06%
2011 6.645.934.000 23.88%
2012 6.868.366.000 3.24%
2013 7.078.577.000 2.97%
2014 7.475.963.000 5.32%
2015 8.030.455.000 6.9%
2016 8.810.602.000 8.85%
2017 7.737.759.000 -13.87%
2018 8.267.673.000 6.41%
2019 8.710.100.000 5.08%
2020 9.240.715.000 5.74%
2021 9.833.471.000 6.03%
2022 10.655.441.000 7.71%
2023 11.400.046.000 6.53%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Hypera S.A. Assets
Year Assets Growth
2005 257.600.000
2006 319.227.000 19.31%
2007 1.970.587.000 83.8%
2008 3.565.389.000 44.73%
2009 6.287.485.000 43.29%
2010 9.987.182.000 37.04%
2011 13.325.286.000 25.05%
2012 12.656.511.000 -5.28%
2013 12.501.987.000 -1.24%
2014 13.887.691.000 9.98%
2015 15.823.430.000 12.23%
2016 11.485.416.000 -37.77%
2017 10.130.437.000 -13.38%
2018 10.556.983.000 4.04%
2019 11.919.475.000 11.43%
2020 17.249.810.000 30.9%
2021 19.817.962.000 12.96%
2022 23.755.633.000 16.58%
2023 24.270.087.000 2.12%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Hypera S.A. Liabilities
Year Liabilities Growth
2005 217.300.000
2006 281.827.000 22.9%
2007 1.277.899.000 77.95%
2008 1.648.861.000 22.5%
2009 2.850.175.000 42.15%
2010 4.928.091.000 42.16%
2011 6.679.352.000 26.22%
2012 5.788.145.000 -15.4%
2013 5.423.410.000 -6.73%
2014 6.411.728.000 15.41%
2015 7.792.975.000 17.72%
2016 2.674.814.000 -191.35%
2017 2.392.678.000 -11.79%
2018 2.289.310.000 -4.52%
2019 3.209.375.000 28.67%
2020 8.009.095.000 59.93%
2021 9.984.491.000 19.78%
2022 13.100.192.000 23.78%
2023 12.870.041.000 -1.79%

Hypera S.A. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
12.95
Net Income per Share
2.8
Price to Earning Ratio
12.85x
Price To Sales Ratio
2.77x
POCF Ratio
10.73
PFCF Ratio
18.22
Price to Book Ratio
2
EV to Sales
3.71
EV Over EBITDA
9.88
EV to Operating CashFlow
14.34
EV to FreeCashFlow
24.35
Earnings Yield
0.08
FreeCashFlow Yield
0.05
Market Cap
22,72 Bil.
Enterprise Value
30,37 Bil.
Graham Number
33.65
Graham NetNet
-11.54

Income Statement Metrics

Net Income per Share
2.8
Income Quality
1.28
ROE
0.16
Return On Assets
0.06
Return On Capital Employed
0.12
Net Income per EBT
1.1
EBT Per Ebit
0.57
Ebit per Revenue
0.33
Effective Tax Rate
-0.09

Margins

Sales, General, & Administrative to Revenue
0.01
Research & Developement to Revenue
0.02
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.63
Operating Profit Margin
0.33
Pretax Profit Margin
0.19
Net Profit Margin
0.21

Dividends

Dividend Yield
0.03
Dividend Yield %
3.35
Payout Ratio
0.44
Dividend Per Share
0.25

Operating Metrics

Operating Cashflow per Share
3.35
Free CashFlow per Share
1.97
Capex to Operating CashFlow
-0.41
Capex to Revenue
-0.11
Capex to Depreciation
-3.98
Return on Invested Capital
0.14
Return on Tangible Assets
0.14
Days Sales Outstanding
152.15
Days Payables Outstanding
115.74
Days of Inventory on Hand
266.94
Receivables Turnover
2.4
Payables Turnover
3.15
Inventory Turnover
1.37
Capex per Share
-1.38

Balance Sheet

Cash per Share
3,02
Book Value per Share
18,00
Tangible Book Value per Share
0.05
Shareholders Equity per Share
18
Interest Debt per Share
17.44
Debt to Equity
0.87
Debt to Assets
0.41
Net Debt to EBITDA
2.49
Current Ratio
1.89
Tangible Asset Value
0,03 Bil.
Net Current Asset Value
-4,77 Bil.
Invested Capital
0.87
Working Capital
3,82 Bil.
Intangibles to Total Assets
0.47
Average Receivables
3,31 Bil.
Average Payables
1,01 Bil.
Average Inventory
2254809500
Debt to Market Cap
0.43

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Hypera S.A. Dividends
Year Dividends Growth
2011 0
2013 0 0%
2016 0 0%
2017 1 0%
2018 1 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Hypera S.A. Profile

About Hypera S.A.

Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.

CEO
Mr. Breno Toledo Pires de Oliv
Employee
10.301
Address
Av. Magalhães de Castro, 4800
São Paulo, 05676-120

Hypera S.A. Executives & BODs

Hypera S.A. Executives & BODs
# Name Age
1 Mauricio Christovam
Senior Human Resources Officer
70
2 Mr. Breno Toledo Pires de Oliveira
Chief Executive Officer & Director
70
3 Mr. Adalmario Ghovatto Satheler do Couto
Investor Relations Officer & Chief Financial Officer
70
4 Mr. Carlos Roberto Scorsi
Chief Operating officer
70
5 Juliana Aguinaga Damião Salem
Senior Legal Officer & Director
70
6 Joao Felipe Khamis Aguilar
Risks & Compliance Officer
70
7 Mr. Luiz Eduardo Sales Clavis
Vice President of Sales and Marketing & Director
70
8 Mr. Hélio Segouras
Head of Consumer Health
70

Hypera S.A. Competitors